BamSEC and AlphaSense Join Forces
Learn More

Altimmune Inc.

NASDAQ: ALT    
Share price (3/21/25): $5.81    
Market cap (3/21/25): $447 million
Search in Documents
Key Exhibits
External Links

Plans of Reorganization, Merger, Acquisition or Similar Filter

EX-2.1
from 8-K 102 pages Agreement and Plan of Merger and Reorganization by and Among Altimmune, Inc., Springfield Merger Sub, Inc., Springfield Merger Sub, LLC Spitfire Pharma, Inc. and David Collier, as the Stockholder Representative Dated as of July 8, 2019
12/34/56
EX-2.1
from 8-K 75 pages Securities Purchase Agreement
12/34/56
EX-2.1
from 8-K 19 pages Amendment No. 1 to Agreement and Plan of Merger
12/34/56
EX-2.1
from 425 19 pages Amendment No. 1 to Agreement and Plan of Merger
12/34/56
EX-2.1
from 8-K 109 pages Agreement and Plan of Merger and Reorganization by and Among Pharmathene, Inc., Mustang Merger Sub Corp I Inc., Mustang Merger Sub II LLC Altimmune, Inc., and Shareholder Representative Services LLC, as Securityholders’ Representative Dated as of January 18, 2017
12/34/56
EX-2.1
from 425 109 pages Agreement and Plan of Merger and Reorganization by and Among Pharmathene, Inc., Mustang Merger Sub Corp I Inc., Mustang Merger Sub II LLC Altimmune, Inc., and Shareholder Representative Services LLC, as Securityholders’ Representative Dated as of January 18, 2017
12/34/56
EX-2.1
from 8-K 4 pages Termination Agreement
12/34/56
EX-2.1
from 8-K 101 pages Agreement and Plan of Merger Among Pharmathene, Inc., Taurus Merger Sub, Inc., Theraclone Sciences, Inc., and Steven Gillis, PH.D., as Securityholders’ Representative Dated as of July 31, 2013
12/34/56
EX-2.1
from 425 101 pages Agreement and Plan of Merger Among Pharmathene, Inc., Taurus Merger Sub, Inc., Theraclone Sciences, Inc., and Steven Gillis, PH.D., as Securityholders’ Representative Dated as of July 31, 2013
12/34/56
EX-2.1
from 8-K 7 pages Dated 2nd April 2008 Amendment Agreement Among Avecia Investments Limited and Others and Pharmathene, Inc. and Others Relating to a Sale and Purchase Agreement Entered Into on 20 March 2008 in Respect of the Avecia Vaccines Business Contents
12/34/56
EX-2.1
from 8-K 106 pages Dated 20 March 2008 Sale and Purchase Agreement Among Avecia Investments Limited and Others and Pharmathene, Inc. and Others Relating to the Avecia Vaccines Business Contents
12/34/56
EX-2.1
from DEFA14A 91 pages Agreement and Plan of Merger Dated as of January 19, 2007 by and Among Healthcare Acquisition Corp., Pai Acquisition Corp. and Pharmathene, Inc
12/34/56
EX-2.1
from 8-K 91 pages Agreement and Plan of Merger Dated as of January 19, 2007 by and Among Healthcare Acquisition Corp., Pai Acquisition Corp. and Pharmathene, Inc
12/34/56